Author:
Bergmann Arnfin,Stangel Martin,Weih Markus,van Hövell Philip,Braune Stefan,Köchling Monika,Roßnagel Fabian
Abstract
“Real-world evidence (RWE)” is becoming increasingly important in order to integrate the results of randomized studies into everyday clinical practice. The data collection of RWE is usually derived from large-scale national and international registries, often driven by academic centers. We have developed a digitalized doctor–patient platform called DESTINY (DatabasE-assiSted Therapy decIsioN support sYstem) that is utilized by NeuroTransData (NTD), a network of neurologists and psychiatrists throughout Germany. This platform can be integrated into everyday practice and, as well as being used for scientific evaluations in healthcare research, can also serve as an individual, personalized treatment application. Its various modules allow for a timely identification of side-effects or interactions of treatments, can involve patients via the “My NTC Health Guide” portal, and can collect data of individual disease histories that are integrated into innovative algorithms, e.g., for the prediction of treatment response [currently available for multiple sclerosis (MS), with other indications in the pipeline]. Here, we describe the doctor–patient platform DESTINY for outpatient neurological practices and its contribution to improved treatment success as well as reduction of healthcare costs. Platforms like DESTINY may facilitate the goal of personalized healthcare.
Reference32 articles.
1. DeutschesÄrzteblatt
Digitalisierung: Das Berufsbild des Arztes Wird Sich Wandeln.2017
2. EichlerHG
Real World Evidence (RWE) – An Introduction; How is it Relevant for the Medicines Regulatory System?2018
3. Regulatory Perspective on Real World Evidence (RWE) in Scientific Advice2018
4. National MS registries;Flachenecker;J Neurol.,2008
5. Defining secondary progressive multiple sclerosis;Lorscheider;Brain.,2016
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献